Your browser doesn't support javascript.
loading
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort.
Rua-Figueroa, Iñigo; García de Yébenes, M Jesus; Martinez-Barrio, Julia; Galindo Izquierdo, Maria; Calvo Alén, Jaime; Fernandez-Nebro, Antonio; Menor-Almagro, Raúl; Carmona, Loreto; Tejera Segura, Beatriz; Tomero, Eva; Freire-González, Mercedes; Sangüesa, Clara; Horcada, Loreto; Blanco, Ricardo; Uriarte Itzazelaia, Esther; Narváez, Javier; Rosas Gómez de Salazar, José Carlos; Gómez-Sabater, Silvia; Morales, Claudia Moriano; Andreu, Jose L; Segarra, Vicente Torrente; Aurrecoechea, Elena; Perez, Ana; Nóvoa Medina, Javier; Salgado, Eva; Lozano-Rivas, Nuria; Montilla, Carlos; Ruiz-Lucea, Esther; Arevalo, Marta; Iñiguez, Carlota; García-Villanueva, María Jesús; Exposito, Lorena; Ibáñez-Barceló, Mónica; Bonilla, Gema; Carrión-Barberà, Irene; Erausquin, Celia; Fragio Gil, Jorge Juan; Pecondón, Angela; Toyos, Francisco J; Cobo, Tatiana; Muñoz-Jiménez, Alejandro; Oller, Jose; Nolla, Joan M; Pego-Reigosa, J M.
Afiliação
  • Rua-Figueroa I; Department of Rheumatology, Hospital Universitario Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain iruafer@gobiernodecanarias.org.
  • García de Yébenes MJ; Institute for Musculoskeletal Health, Madrid, Spain.
  • Martinez-Barrio J; Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Galindo Izquierdo M; Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Calvo Alén J; Department of Rheumatology, Hospital Sierrallana, Vitoria, Spain.
  • Fernandez-Nebro A; UGC de Reumatología, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain.
  • Menor-Almagro R; Department of Rheumatology, Jerez Hospital, Jerez, Spain.
  • Carmona L; Instituto de Salud Musculoesquelética (INMUSC), Madrid, Spain.
  • Tejera Segura B; Department of Rheumatology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.
  • Tomero E; Department of Rheumatology, Hospital Universitario de la Princesa, Instituto de Investigación La Princesa, Madrid, Spain.
  • Freire-González M; Department of Rheumatology, University Hospital Complex of A Coruña, A Coruña, Spain.
  • Sangüesa C; Department of Rheumatology, Hospital Germán Trias i Pujol, Barcelona, Spain.
  • Horcada L; Department of Rheumatology, Hospital de Navarra, Pamplona, Spain.
  • Blanco R; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  • Uriarte Itzazelaia E; Donostia Ospitalea, San Sebastian, Spain.
  • Narváez J; Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain.
  • Rosas Gómez de Salazar JC; Department of Rheumatology, Marina Baixa Hospital, Alicante, Spain.
  • Gómez-Sabater S; Department of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain.
  • Morales CM; University Hospital Centre León, Leon, Spain.
  • Andreu JL; Department of Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Segarra VT; Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain.
  • Aurrecoechea E; Department of Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain.
  • Perez A; Immune System Diseases and Oncology Service, University Hospital "Príncipe de Asturias", Alcala de Henares, Spain.
  • Nóvoa Medina J; Department of Rheumatology, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas GC, Spain.
  • Salgado E; Department of Rheumatology, Complejo Hospitalario de Orense, Ourense, Spain.
  • Lozano-Rivas N; Department of Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain.
  • Montilla C; Department of Rheumatology, Hospital Clinico Universitario Salamanca, Salamanca, Spain.
  • Ruiz-Lucea E; Basurto University Hospital, Bilbao, Spain.
  • Arevalo M; Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain.
  • Iñiguez C; University Hospital Lucus Augusti, Lugo, Spain.
  • García-Villanueva MJ; Hospital Universitario Ramon y Cajal, Madrid, Spain.
  • Exposito L; Hospital Universitario de Canarias, La Laguna, Spain.
  • Ibáñez-Barceló M; Department of Rheumatology, Son Llatzer Hospital, Mallorca, Spain.
  • Bonilla G; Department of Rheumatology, La Paz University Hospital, Madrid, Spain.
  • Carrión-Barberà I; Department of Rheumatology, Hospital del Mar, Barcelona, Spain.
  • Erausquin C; Department of Rheumatology, Hospital Universitario Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain.
  • Fragio Gil JJ; La Fe University and Polytechnic Hospital, Valencia, Spain.
  • Pecondón A; Miguel Servet University Hospital, Zaragoza, Spain.
  • Toyos FJ; Department of Rheumatology, Hospital Virgen Macarena, Sevilla, Spain.
  • Cobo T; Hospital Infanta Sofía, Madrid, Spain.
  • Muñoz-Jiménez A; Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Oller J; Doctor Peset University Hospital, Valencia, Spain.
  • Nolla JM; Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain.
  • Pego-Reigosa JM; Department of Rheumatology, University Hospital Complex of Vigo, Vigo, Spain.
Lupus Sci Med ; 11(1)2024 Apr 08.
Article em En | MEDLINE | ID: mdl-38589223
ABSTRACT

OBJECTIVE:

To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate it in a large multicentre lupus cohort.

METHODS:

We used data from the prospective phase of RELESSER (RELESSER-PROS), the SLE register of the Spanish Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLESIS score, plus all other potential predictors identified in a literature review. Performance was analysed using the C-statistic and the area under the receiver operating characteristic curve (AUROC). Internal validation was carried out using a 100-sample bootstrapping procedure. ORs were transformed into score items, and the AUROC was used to determine performance.

RESULTS:

A total of 1459 patients who had completed 1 year of follow-up were included in the development cohort (mean age, 49±13 years; 90% women). Twenty-five (1.7%) had experienced ≥1 severe infection. According to the adjusted multivariate model, severe infection could be predicted from four variables age (years) ≥60, previous SLE-related hospitalisation, previous serious infection and glucocorticoid dose. A score was built from the best model, taking values from 0 to 17. The AUROC was 0.861 (0.777-0.946). The cut-off chosen was ≥6, which exhibited an accuracy of 85.9% and a positive likelihood ratio of 5.48.

CONCLUSIONS:

SLESIS-R is an accurate and feasible instrument for predicting infections in patients with SLE. SLESIS-R could help to make informed decisions on the use of immunosuppressants and the implementation of preventive measures.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Sistêmico Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lupus Sci Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lúpus Eritematoso Sistêmico Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lupus Sci Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha